Home GPCR & G Protein CXCR antagonist Plerixafor (AMD3100) 8HCl

solo para uso en investigación

Plerixafor (AMD3100) 8HCl CXCR antagonist

Cat. No.: S3013

Plerixafor (AMD3100, JM 3100,Plerixafor Octahydrochloride,AMD3100 octahydrochloride,SID791 octahydrochloride) 8HCl is the hydrochloride of Plerixafor, a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM in cell-free assays, respectively. Plerixafor can be used as an anti-HIV agent.
Plerixafor (AMD3100) 8HCl CXCR antagonist Chemical Structure

Estructura química

Peso molecular: 794.47

Saltar a

Control de calidad (Quality Control)

Lote: Pureza: 99.90%
99.90

Cultivo celular, tratamiento y concentración de trabajo
(Cell Culture, Treatment & Working Concentration)

Líneas celulares Tipo de ensayo Concentración Tiempo de incubación Formulación Descripción de la actividad PMID
CHOK1 cells Function assay Displacement of [125I]SDF1alpha from CXCR4 expressed in CHOK1 cells, IC50=0.81 nM 17715128
GHOST CXCR4 cell line Function assay Inhibitory concentration of compound against HIV-1 LAI strain in GHOST CXCR4 cell line, IC50=0.95 nM 14698189
HEK293 cells Function assay 2 days Antiviral activity against T20-resistant HIV1 NL4-3 infected in HEK293 cells assessed as inhibition of viral replication after 2 days, IC50=2.3 nM 19451305
PBMC cells Function assay Effective concentration of compound against HIV-1 89.6 strain in PBMC cells, EC50=3.8 nM 14698189
human MT4 cells Function assay 4 days Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus replication after 4 days by MTT assay, EC50=4 nM 20043638
human Jurkat cells Function assay Antagonist activity at CXCR4 in human Jurkat cells assessed as inhibition of SDF1-induced cell migration, IC50=27.4 nM 19188071
MT-4 cells Function assay Effective concentration of compound against HIV-1 IIIB strain in MT-4 cells, EC50=65 nM 14698189
rat IR983F cells Function assay Displacement of [125I]CXCL12 from CXCR4 in rat IR983F cells, IC50=108 nM 19053768
CEM-SS cells Function assay Effective concentration of compound against HIV-1 LAI strain in CEM-SS cells, EC50=127 nM 14698189
human HL60 cells Function assay Displacement of [125I]SDF1alpha from CXCR4 in human HL60 cells, IC50=15.2 μM 19188071
human MOLT4 cells Function assay 1000 nM Inhibition of Mab 12G5 binding to CXCR4 expressed in human MOLT4 cells at 1000 nM by FACS analysis 19451305
human MT2 cells Function assay 1 ug/mL 4 days Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral p24 antigen production at 1 ug/mL after 4 days by ELISA 21168336
human U87 cells Function assay 1000 nM Antagonist activity at CXCR4 in human U87 cells assessed as inhibition of SDF1-induced modulation of cAMP production at 1000 nM by TR-FRET assay 17958344
MT4 Antiviral assay Antiviral activity against HIV1 3B assessed as reduction in cytopathic effect in MT4 cells, EC50=0.011μM 17034122
U87 Function assay 15 mins Antagonist activity at human CXCR4 expressed in human U87 cells expressing CD4 assessed as inhibition of CXCL12-induced cAMP production pretreated for 15 mins before forskolin challenge by TR-FRET analysis, IC50=0.695μM 21105715
MT4 Antiviral assay Antiviral activity against X4-tropic HIV1 NL4.3 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity, EC50=0.062μM 22579418
MT4 Antiviral assay 5 days Antiviral activity against HIV1 infected in MT4 cells expressing CXCR4 assessed as inhibition of virus-induced cytopathic effect after 5 days, EC50=0.002μM 22909088
CHO Function assay Binding affinity to human recombinant CXCR4 expressed in CHO cells, Kb=0.077μM 22909088
CHO Function assay Antagonist activity at human recombinant CXCR4 expressed in CHO cells assessed as inhibition of SDF1a-induced electrical impedance by dielectric spectroscopic analysis, IC50=0.26μM 22909088
CD44null Function assay 7 days Effect on human GBM2 cell differentiation assessed as increase in CD44null cells after 7 days by flow cytometric analysis 22909088
CD44null Function assay 7 days Effect on human GBM1 cell differentiation assessed as increase in CD44null cells after 7 days by flow cytometric analysis 22909088
Haga clic para ver más datos experimentales de líneas celulares

Información química, almacenamiento y estabilidad (Chemical Information, Storage & Stability)

Peso molecular 794.47 Fórmula

C28H54N8.8HCl

 Almacenamiento (Desde la fecha de recepción)
Nº CAS 155148-31-5 Descargar SDF Almacenamiento de soluciones madre

Sinónimos JM 3100 8HCl,Plerixafor Octahydrochloride,AMD3100 octahydrochloride,SID791 octahydrochloride Smiles C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3.Cl.Cl.Cl.Cl.Cl.Cl.Cl.Cl

Solubilidad (Solubility)

In vitro
Lote:

Water : 100 mg/mL

DMSO : Insoluble
(El DMSO contaminado con humedad puede reducir la solubilidad. Usar DMSO fresco y anhidro.)

Ethanol : Insoluble

Calculadora de Molaridad

Masa Concentración Volumen Peso molecular
Calculadora de Dilución Calculadora de Peso Molecular

In vivo
Lote:

Calculadora de formulación in vivo (Solución clara)

Paso 1: Introduzca la información a continuación (Recomendado: Un animal adicional para tener en cuenta la pérdida durante el experimento)

mg/kg g μL

Paso 2: Introduzca la formulación in vivo (Esto es solo la calculadora, no la formulación. Por favor, contáctenos primero si no hay una formulación in vivo en la sección de Solubilidad.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Resultados del cálculo:

Concentración de trabajo: mg/ml;

Método para preparar el líquido maestro de DMSO: mg fármaco predissuelto en μL DMSO ( Concentración del líquido maestro mg/mL, Por favor, contáctenos primero si la concentración excede la solubilidad del DMSO del lote del fármaco. )

Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadirμL PEG300, mezclar y clarificar, luego añadirμL Tween 80, mezclar y clarificar, luego añadir μL ddH2O, mezclar y clarificar.

Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadir μL Aceite de maíz, mezclar y clarificar.

Nota: 1. Por favor, asegúrese de que el líquido esté claro antes de añadir el siguiente disolvente.
2. Asegúrese de añadir el (los) disolvente(s) en orden. Debe asegurarse de que la solución obtenida, en la adición anterior, sea una solución clara antes de proceder a añadir el siguiente disolvente. Se pueden utilizar métodos físicos como el vórtice, el ultrasonido o el baño de agua caliente para ayudar a la disolución.

Mecanismo de acción (Mechanism of Action)

Targets/IC50/Ki
CXCL12
(Cell-free assay)
5.7 nM
CXCR4
(Cell-free assay)
44 nM
In vitro

Plerixafor inhibits CXCL12-mediated chemotaxis with a potency lightly better than its affinity for CXCR4. Plerixafor also antagonizes SDF-1/CXCL12 ligand binding with an IC50 of 651 nM. Plerixafor inhibits SDF-1 mediated GTP-binding, SDF-1 mediated calcium flux and SDF-1 stimulated chemotaxis with IC50 of 27 nM, 572 nM and 51 nM, respectively. Plerixafor does not inhibit calcium flux against cells expressing CXCR3, CCR1, CCR2b, CCR4, CCR5 or CCR7 when stimulated with their cognate ligands, nor does Plerixafor inhibit receptor binding of LTB4. Plerixafor does not, on its own, induce a calcium flux in the CCRF–CEM cells, which express multiple GPCRs including CXCR4, CCR4 and CCR7.

In vivo

A single topical application of Plerixafor promotes wound healing in diabetic mice by increasing cytokine production, mobilizing bone marrow EPCs, and enhancing the activity of fibroblasts and monocytes/macrophages, thereby increasing both angiogenesis and vasculogenesis. Cohorts of mice are administered with PBS, IGF1, PDGF, SCF, or VEGF for five consecutive days and Plerixafor on the 5th day. The number and size of the colonies are highest in IGF1 plus Plerixafor injected mice compared to PDGF, SCF and VEGF treated groups, in combination with Plerixafor.

Referencias
  • [4] https://pubmed.ncbi.nlm.nih.gov/22342795/

Aplicaciones (Applications)

Métodos Biomarcadores Imágenes PMID
Immunofluorescence CXCR4 β-arrestin2
S3013-IF1
28521261

Información del ensayo clínico (Clinical Trial Information)

(datos de https://clinicaltrials.gov, actualizado el 2024-05-22)

Número NCT Reclutamiento Condiciones Patrocinador/Colaboradores Fecha de inicio Fases
NCT05421416 Not yet recruiting
Stem Cell Transplant Complications
AHS Cancer Control Alberta
 April 1 2024 Phase 2
NCT05343572 Recruiting
Asherman Syndrome|Atrophic Endometrium|Recurrent Implantation Failure
Hugh Taylor|Yale University
 November 1 2023 Early Phase 1
NCT05844527 Recruiting
Wound of Skin|Abdominal Wound
MedRegen LLC
 November 20 2023 Phase 2
NCT05411575 Withdrawn
COVID-19 Acute Respiratory Distress Syndrome|COVID-19
4Living Biotech|4P-Pharma
 July 19 2022 Phase 2
NCT05445128 Terminated
Sickle Cell Disease
Ensoma|bluebird bio
 June 24 2022 Phase 2
NCT05835726 Recruiting
Multiple Myeloma|Daratumumab|Autologous Stem Cell Transplantation|Leukapheresis
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
 January 1 2022 --